kb004
mAbexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2010 (NCT01211691)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Ephrin type-A receptor 3INHIBITOR
EPHA3 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109398 ↗
Also known as
- kb004
- kb-004
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03374943 | Phase 1 | Dec 5, 2017 | Austin Health, Humanigen, Olivia Newton-John Cancer Research Institute |
| NCT01211691 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2010 | Humanigen |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Humanigen | For profit | 2 | 1 | 2 | 2010 |
| Austin Health | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Olivia Newton-John Cancer Research Institute | Academic/Hospital | 1 | 1 | 1 | 2017 |
3 organizations
Page 1 / 1